The Campaign for Sustainable Rx Pricing (CSRxP) released the following statement in response to new analysis from Bloomberg that shows 30 out of 39 of the top drugs in the world had price increases more than double the rate of inflation.
CSRxP Executive Director John Rother said: “Today’s findings are just one more example of drug companies using a broken market to keep prices high. When the sticker price for 30 out of 39 of the most sold drugs goes up by more than double the rate of inflation, consumers are left holding the bag. These price increases year after year compound the problem and the whole scheme is unsustainable.”
# # #